Leiden Dworak - 12 Jan 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Vice President, Finance
Signature
/s/ Leiden Dworak
Issuer symbol
TCRX
Transactions as of
12 Jan 2024
Net transactions value
$0
Form type
4
Filing time
11 Feb 2025, 17:54:39 UTC
Previous filing
24 Jul 2023
Next filing
22 Aug 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +46,875 $0.000000 46,875 12 Jan 2024 Voting Common Stock 46,875 $6.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Leiden Dworak is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 12, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.